[1] No dosage adjustment is required for patients with renal impairment, including end-stage renal disease, though renal function should be monitored if severe gastrointestinal adverse effects occur
Reference Chiappini, Vickers-Smith, Harris, Papanti Pelletier, Corkery and Guirguis29,Reference Arillotta, Floresta, Guirguis, Corkery, Catalani and Martinotti30 Chen et al Reference Chen, Cai, Zou and Fu31 conducted an observational pharmacovigilance study
If what weve talked about when it comes to receptor resistance applies to you, there are a few strategies that might help: Consider switching medications: It could be useful to try switching from Wegovy, which only acts on one type of receptor (GLP-1), to Zepbound, which targets two receptors (GLP-1 and GIP)
doi:10.25259/GJMPBU_16_2022 32
In this sense, it is worthy of note that several BZ delivery platforms and formulations are been assayed in pre-clinical studies (Scalise et al., 2016
Skrivankova VW, Richmond RC, Woolf BAR, et al